
|Videos|December 4, 2021
Dr. Andriole discusses promise of 18F-fluciclovine for managing biochemically recurrent prostate cancer
Author(s)Urology Times staff
“For most men, we can identify the specific site or sites of recurrence, and thereby use a more directed therapy that specifically targets the abnormal sites,” says Gerald L. Andriole, MD.
Advertisement
In this video, Gerald L. Andriole, MD, discusses the background and findings of the study, “Impact of 18F-Fluciclovine PET/CT on plans for ADT in patients with biochemical recurrence of prostate cancer; data analysis from two prospective clinical trials,” presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Andriole is a Robert Killian Royce distinguished professor of urologic surgery at the Washington University School of Medicine in St. Louis, Missouri.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: AUA 2026 Update on Prostate Cancer Early Detection, With Badrinath R. Konety, MBBS
2
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
3
Daniel George, MD, on the significance of the capivasertib approval for PTEN-deficient prostate cancer
4
EV plus pembro approval reframes first conversation in MIBC diagnosis
5













